

Submitter Name: Li-Shiun Chen
Submitted email: li-shiun@wustl.edu

Predicting smoking cessation treatment outcomes with genetic risk scores and biomarkers

Li-Shiun Chen, M.D., M.P.H., Sc.D.¹, Timothy Baker, Ph.D.², Michael Bray, Ph.D.¹, Giang Pham, MPH, Laura Bierut, M.D.¹

¹Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.

²Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Introduction: This study aims to evaluate the potential of polygenetic markers to enhance current treatment by incorporating an individual's genetic and metabolism risk biomarkers.

Methods: We investigated two predictors: a) genome-wide polygenic scores for smoking phenotypes and b) biomarker nicotine metabolite ratio. We evaluated bio-verified end-of-treatment abstinence among smokers in two randomized control trials (N=1,898 including 807 in the Genetically Informed Smoking Cessation Trial (GISC) and 1,091 in the University of Wisconsin Trial).

Results: Both polygenic risk scores for failed smoking cessation and polygenic risk scores for delayed age of smoking initiation predict end-of-treatment abstinence in both trials (meta-analysis OR=0.89, 95%CI=0.80-0.99, p=0.037; meta-analysis OR=1.2, 95%CI=1.1-1.4, p=0.00038 respectively, N=1,592 smokers of European Ancestry). In addition, the nicotine metabolite ratio biomarker predicts treatment response as assessed by end-of-treatment abstinence in 807 GISC trial smokers of both European and non-European Ancestry. Specifically, slow nicotine metabolizers respond better to nicotine replacement vs. placebo (OR=4.7, 95%CI=1.7, 14.9, p=0.0040), but not varenicline vs. placebo (OR=2.5, 95%CI=0.87-8.1, p=0.11). In contrast, normal nicotine metabolizers respond to both nicotine replacement and varenicline vs. placebo (OR=2.04, 95%CI=1.12-3.8, p=0.021; OR=4.15, 95% CI=2.38-7.49, p=9.8e-7 respectively), but varenicline produces significantly higher end-of-treatment abstinence than does nicotine replacement (OR=2.0, 95%CI=1.2-3.3, p=0.0050 for varenicline vs. nicotine replacement).

Conclusion: Polygenic risk scores predicted overall treatment success and the NMR biomarker predicted differential treatment response. These findings strengthen the case that polygenic risk scores and a metabolism biomarker provide complementary information that could be useful for treatment development, treatment assignment, and prediction of outcome.